Project Grant R01AG093434
Award Date 9/1/26
Completion Date 6/30/31
Dollars Obligated $763K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) provides $2,357,335 to study neuronal dysfunction in Down syndrome (DS) and its link to Alzheimer's disease (AD). The key products and services delivered under this award include: Utilizing induced pluripotent stem cell (iPSC)-derived cortical organoids and assembloids to examine the cellular, transcriptomic, and motility-related...
- The National Institutes of Health Office of the Director awarded University of California Irvine $6.132 million on August 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate the neurobiological basis for cognitive dysfunction and dementia in aging adults with Down syndrome. The project uses spatial multi-omics techniques—combining transcriptomics, epigenomics, and proteomics—to analyze over 100 clinically characterized brain samples from individuals with Down...
- The National Institutes of Health (NIH) Office of the Director awarded a Project Grant of $1,896,457.00 under the Trans-NIH Research Support program (CFDA 93.310) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the project "BRAIN DEVELOPMENT IN DOWN SYNDROME DURING FETAL AND EARLY POSTNATAL AGES". The grant, awarded on Sep 18, 2024, aims to confirm earlier findings on brain abnormalities in Down syndrome (DS) using advanced...
- The National Institutes of Health Office of the Director awarded Brigham & Women's Hospital Inc. $1.602718 million on September 15, 2025, under the Trans-NIH Research Support program (CFDA 93.310) to conduct a Phase 1 clinical trial evaluating nicotinamide mononucleotide (NMN), a NAD+ precursor, for safety, tolerability, pharmacokinetics, and pharmacodynamics in adults with Down syndrome as a potential intervention to prevent or slow Alzheimer's disease progression. The trial employs a...
- The Department of Health and Human Services National Institutes of Health Office of the Director awarded the University of Wisconsin System $568,615 on September 2, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate the molecular mechanisms underlying synaptic deficiency in Down syndrome. The research project, titled "Molecular Mechanisms Underlying Synaptic Deficiency in Down Syndrome" (R01HD120347), will use isogenic trisomy 21 disorder-specific human...
- The National Institutes of Health Office of the Director awarded $2.693 million to the University of Wisconsin–Madison on September 15, 2025, under the Trans-NIH Research Support program (CFDA 93.310) to establish an Alzheimer's disease biomarker clock in Down syndrome using positron emission tomography and plasma analytes. The research addresses the underrepresentation of individuals with Down syndrome in Alzheimer's disease therapeutic trials by characterizing biomarker progression in this...
- The National Institute on Aging, within the Department of Health and Human Services, awarded The Medical College of Wisconsin, Inc. $429,000 on February 1, 2026, under the Aging Research program (CFDA 93.866) to investigate how overexpression of human chromosome 21 (HSA21) orthologs affects neurodegeneration during aging in Caenorhabditis elegans. The project addresses variability in dementia onset among individuals with Down syndrome, which results from trisomy 21. While approximately 75...
- The National Institute on Aging awarded Brigham & Women's Hospital $889,734 on September 1, 2026, under the Aging Research program (CFDA 93.866) to advance care planning for older individuals with Down syndrome experiencing early-onset and accelerated dementia. The award funds a mechanistic evaluation of the Serious Illness Care Program (SICP)—a multi-modal intervention comprising a structured conversation guide and clinician training—tailored to older individuals with Down syndrome facing...
- The National Institutes of Health Office of the Director awarded the University of New Mexico Health Sciences Center $419,375 on July 1, 2026, under the Trans-NIH Research Support program (CFDA 93.310) to investigate mechanisms of vascular dysfunction in Down syndrome. The research examines endothelial dysfunction and glycocalyx depletion in a mouse model of Down syndrome (TCMAC21 mice) to understand cardiovascular disease risk in the Down syndrome population. The study investigates how...
- The National Institute on Aging awarded Beth Israel Deaconess Medical Center, Inc. $3,481,644 on August 1, 2026, under the Aging Research program (CFDA 93.866) to investigate mechanisms by which excessive amyloid-beta peptides impair brain lymphatic function and contribute to Alzheimer's disease and Down syndrome. The research program comprises three strategic aims. The first involves extensive molecular, cellular, structural, and functional analyses of brain lymphatics in mouse models of...